Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis
Randomized Double Blind Trial Comparing the Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin for Initial Treatment of Patients With Hepatitis C With Genotype 1 or 4 and Severe Fibrosis
Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
A PHASE2 clinical study on Fibrosis and Hepatitis C, Chronic, this trial is ongoing. The trial is conducted by French National Agency for Research on AIDS and Viral Hepatitis and has accumulated 5 data snapshots since 2004. Infectious disease trials contribute critical data for public health response and treatment development.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Sep 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- French National Agency for Research on AIDS and Viral Hepatitis
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Pessac, France